Product Description
Cefdinir is used to treat certain infections caused by bacteria such as bronchitis (infection of the airway tubes leading to the lungs); pneumonia; and infections of the skin, ears, sinuses, throat, and tonsils.. Cefdinir is in a class of medications called cephalosporin antibiotics. It works by killing bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a698001.html)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Bangladesh | Chile | Colombia | Ecuador | Egypt | India | Indonesia | Ireland | Jordan | Korea | Lebanon | Mexico | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Sweden | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Highest Development Phases
Phase 1: Abscess|Anthrax|Blepharitis|Bronchitis, Chronic|Carbuncle|Cellulitis|Cystitis|Erysipelas|Escherichia coli Infections|Folliculitis|Haemophilus Infections|Hidradenitis|Inflammation|Influenza, Human|Klebsiella Infections|Laryngitis|Lymphadenitis|Lymphangitis|Mastitis|Otitis Media|Otitis Media, Suppurative|Paronychia|Pharyngitis|Pneumonia|Pneumonia, Bacterial|Proteus Infections|Pyelonephritis|Pyoderma|Scarlet Fever|Sinusitis|Surgical Wound Infection|Tonsillitis|Urethritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20202701 | P1 |
Not yet recruiting |
Cystitis|Klebsiella Infections|Otitis Media|Haemophilus Infections|Pyoderma|Sinusitis|Proteus Infections|Pneumonia, Bacterial|Tonsillitis|Influenza, Human|Bronchitis, Chronic|Escherichia coli Infections|Pyelonephritis|Lymphadenitis|Pharyngitis|Scarlet Fever|Laryngitis |
None |
|
| CTR20132519 | P1 |
Recruiting |
Erysipelas|Pyoderma|Proteus Infections|Pharyngitis|Urethritis|Tonsillitis|Escherichia coli Infections|Influenza, Human|Mastitis|Cellulitis|Haemophilus Infections|Lymphadenitis|Carbuncle|Sinusitis|Blepharitis|Abscess|Bronchitis, Chronic|Surgical Wound Infection|Pneumonia|Paronychia|Klebsiella Infections|Pyelonephritis|Folliculitis|Cystitis|Otitis Media |
None |
|
| CTR20211160 | P1 |
Not yet recruiting |
Abscess|Escherichia coli Infections|Otitis Media, Suppurative|Pyoderma|Pyelonephritis|Proteus Infections|Pharyngitis|Paronychia|Pneumonia|Erysipelas|Folliculitis|Scarlet Fever|Haemophilus Infections|Sinusitis|Inflammation|Carbuncle|Cystitis|Klebsiella Infections|Anthrax|Influenza, Human|Hidradenitis|Cellulitis|Bronchitis, Chronic|Lymphangitis |
None |
|
| CTR20130418 | P1 |
Active, not recruiting |
Escherichia coli Infections|Klebsiella Infections|Proteus Infections|Haemophilus Infections|Influenza, Human |
None |